Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer/AstraZeneca: part deux?

This article was originally published in Scrip

Executive Summary

So Pfizer has walked away from AstraZeneca. For those of us who earn a living from analyzing the ups and downs and ins and outs of the pharmaceutical industry, it's a bit of a relief to be honest, and that's not a comment on the relative merits of the deal. It's just … we can start writing about other things again, like drug development and innovative science! The kind of stuff that Pascal Soriot has spent the last month promising will come our way if AstraZeneca was just left alone to get on with things. We at Scrip can hardly wait for AstraZeneca to start delivering on all the promises Mr Soriot has been making to the company's investors, to the UK parliament, and to the rest of us. From key data readouts and Phase III starts in short term, to numerous new product launches and a return to growth in the medium term, and potential revenues of $45bn in the long term. Heady stuff.

Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts